arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Dogwood Therapeutics, Inc.

DWTX

$1.83 ▲ +0.07 (+3.98%) at close

7 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Dogwood Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $9.1M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -37.6% ↘

FCF / Share $-3.14 ↗

Trailing P/E —

Price / Book 0.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-34.26M

↓ -177.4% —

FCF / Share Free cash flow per share

$-3.14

↑ +63.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	43.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-77.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-535.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	42.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	8.6% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-177.4% Weak ↓ Weak Declining Year-over-year change in net income	-133.2% Weak ↓ Weak Declining Year-over-year change in net income	56.8% Excellent ↑ Excellent Improving Year-over-year change in net income	23.3% Good Good Year-over-year change in net income	-54.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	63.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-31.9% Weak ↑ Weak Improving Year-over-year change in free cash flow	-526.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	45.0% Excellent Excellent Year-over-year change in free cash flow	-138.3% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
FCF / Net Income (x)	0.46x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.38x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-37.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	120.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-113.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-132.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-85.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-26.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-31.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-130.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-147.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-99.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-31.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-45.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-405%)	122.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+713%)	-139.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1027%)	-167.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1214%)	-110.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-834%)	-34.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-330%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-797.18x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-6.52M	$-14.85M	$-3.32M	$-7.03M	$-14.01M	$-29.80M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-7.13	$-12.52	$-7.05	$-1.11	$-1.92	$-2.10	—
Free Cash Flow per Share (USD)	$-3.14	$-8.55	$-6.48	$-1.04	$-1.88	$-0.79	—
Book Value per Share (USD)	$2.52	$-0.36	$4.94	$0.40	$1.74	$3.61	—
Tangible Book Value per Share (USD)	$-0.22	$-3.16	$4.94	$0.40	$1.74	$3.61	—
Basic Weighted Avg Shares (shares)	4.98M	1.03M	751,071	11.07M	8.33M	4.93M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$5.37M	$13.37M	$3.81M	$7.33M	$14.50M	$29.94M	—
Total Equity (USD)	$74.90M	$-10.12M	$3.81M	$7.33M	$14.50M	$29.94M	$-5.02M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$2.06K	$12.18K	—	—	—	—	—
Net Income, GAAP (USD)	$-34.26M	$-12.35M	$-5.30M	$-12.25M	$-15.96M	$-10.35M	—
Operating Cash Flow (USD)	$-15.62M	$-8.79M	$-4.87M	$-11.47M	$-15.69M	$-3.90M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Dogwood Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DWTX with peers